File downloaded on 2026-11-09
Source URL: https://medicines.health.europa.eu/veterinary/en/600000035828

Furosoral 40 mg tablets for dogs and cats

Authorised

- Furosemide

Product identification

Medicine name:
Furosoral 40 mg tablets for dogs and cats

Active substance:
Furosemide

Target species:
Dog
Cat

Route of administration:
Oral use

Product details

Active substance and strength:
Furosemide
40.00 milligram(s) / 1.00 Tablet

Pharmaceutical form:
Tablet

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QC03CA01

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Norway

Available in:
Norway

Package description:
Cardboard box of 5 Aluminium-PVDC/PVC blisters with 10 tablets each
Cardboard box of 100 Aluminium-PVDC/PVC blisters with 10 tablets each.
Cardboard box of 10 Aluminium-PVDC/PVC blisters with 10 tablets each.
Cardboard box of 2 Aluminium-PVDC/PVC blisters with 10 tablets each
Cardboard box of 25 Aluminium-PVDC/PVC blisters with 10 tablets each.
Cardboard box of 7 Aluminium-PVDC/PVC blisters with 10 tablets each
Cardboard box of 6 Aluminium-PVDC/PVC blisters with 10 tablets each
Cardboard box of 50 Aluminium-PVDC/PVC blisters with 10 tablets each.
Cardboard box of 4 Aluminium-PVDC/PVC blisters with 10 tablets each
Cardboard box of 3 Aluminium-PVDC/PVC blisters with 10 tablets each
Cardboard box of 1 Aluminium-PVDC/PVC blister with 10 tablets each
Cardboard box of 8 Aluminium-PVDC/PVC blisters with 10 tablets each
Cardboard box of 9 Aluminium-PVDC/PVC blisters with 10 tablets each
Cardboard box containing 10 separate cardboard boxes, each containing 1 blister of 10 tablets.
Cardboard box of 1 Aluminium-PVDC/PE/PVC blister with 10 tablets, respectively corresponding to 10 tablets per box.
Cardboard box of 2 Aluminium-PVDC/PE/PVC blisters with 10 tablets each, respectively corresponding to 20 tablets per box.
Cardboard box of 3 Aluminium-PVDC/PE/PVC blisters with 10 tablets each, respectively corresponding to 30 tablets per box.
Cardboard box of 4 Aluminium-PVDC/PE/PVC blisters with 10 tablets each, respectively corresponding to 40 tablets per box.

Cardboard box of 5 Aluminium-PVDC/PE/PVC blisters with 10 tablets each, respectively corresponding to 50 tablets per box.
Cardboard box of 6 Aluminium-PVDC/PE/PVC blisters with 10 tablets each, respectively corresponding to 60 tablets per box.
Cardboard box of 7 Aluminium-PVDC/PE/PVC blisters with 10 tablets each, respectively corresponding to 70 tablets per box.
Cardboard box of 8 Aluminium-PVDC/PE/PVC blisters with 10 tablets each, respectively corresponding to 80 tablets per box.
Cardboard box of 9 Aluminium-PVDC/PE/PVC blisters with 10 tablets each, respectively corresponding to 90 tablets per box.
Cardboard box of 10 Aluminium-PVDC/PE/PVC blisters with 10 tablets each, respectively corresponding to 100 tablets per box.
Cardboard box of 25 Aluminium-PVDC/PE/PVC blisters with 10 tablets each, respectively corresponding to 250 tablets per box.
Cardboard box of 50 Aluminium-PVDC/PE/PVC blisters with 10 tablets each, respectively corresponding to 500 tablets per box.
Cardboard box of 100 Aluminium-PVDC/PE/PVC blisters with 10 tablets each, respectively corresponding to 1000 tablets per box.

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Generic application (Article 13(1) of Directive No 2001/82/EC)

Marketing authorisation holder:
Le Vet. Beheer B.V.

Marketing authorisation date:
16/03/2016

Manufacturing sites for batch release:
Artesan Pharma GmbH & Co. KG
Lelypharma B.V.
Genera d.d.

Responsible authority:
Norwegian Medical Products Agency

Authorisation number:
14-10174

Date of authorisation status change:
14/03/2019

Reference member state:
Netherlands

Procedure number:
NL/V/0192/002

Concerned member states:
Austria Belgium Croatia Cyprus Czechia Denmark Estonia Finland France Germany Greece Hungary Iceland Ireland Italy Latvia Lithuania Luxembourg Norway Poland Portugal Romania Slovakia Slovenia Spain Sweden United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.

Combined File of all Documents